::: Welcome to Conservation Genome Resource Bank for Korean Wildlife :::
 
17_c.gif ¹®ÇåÁ¤º¸
17_c.gif ¾ß»ýµ¿¹°°ü·Ã ÀÚ·á ¹× ¼Ò½Ä
17_c.gif Á¾Á¤º¸
17_c.gif º¸ÀüÀ¯ÀüÇÐ/º¸Àü»ý¹°ÇÐ ÀÚ·á
17_c.gif ¾ß»ýµ¿¹°ÀÇÇÐ ¼Ò½Ä ¹× ÀÚ·á
  - õ¿¬±â³ä¹°ÀÇ ´ë»ó
sound.gif °¶·¯¸®
sound.gif ÀÚÀ¯°Ô½ÃÆÇ (¿¾³¯ °Ô½ÃÆÇ)
sound.gif °ü·Ã»çÀÌÆ®
sound.gif ÀÚ·á½Ç
sound.gif Ã£¾Æ¿À½Ã´Â ±æ
¾ß»ýµ¿¹°ÀÇÇÐ ¼Ò½Ä ¹× ÀÚ·á

View Article
Name
  ¿î¿µÀÚ 2005-11-21 17:19:33 | Hit : 17690 | Vote : 7441
Subject   [ÀÚ·á] Vaccination against echinococcosis (?)
Ther Umsch. 2005 Oct;62(10):685-93. Related Articles, Links  


Vaccination against echinococcosis (?)

[Article in German]

Gottstein B.

Institut fur Parasitologie, Universitat Bern. bruno.gottstein@ipa.unibe.ch

Two species of the genus Echinococcus occur sympatrically in central Europe, namely Echinococcus multilocularis, the causative agent of alveolar echinococcosis (AE), and E. granulosus, resulting in cystic echinococcosis (CE) in humans. The endemic area of Europe demonstrates an annual incidence of 0.02 to 1.4 new AE cases per 100000 inhabitants. The importance of the disease refers primarily to the high lethality observed in untreated cases. Therapeutically, radical surgical resection of hepatic lesions followed by continuous benzimidazole-therapy is anticipated. Recently, the strategic control of cystic echinococcosis in humans has considerably been improved by the development of an effective and efficient vaccine that will indirectly prevent humans from infection. The vaccine protects animal intermediate hosts (mainly farm ruminants), thus the lack of hydatid cysts in these animals will prevent dogs to become infected. This on the long-term will result in an abrogation of infection sources (Echinococcus eggs) for humans (and other intermediate hosts). Principally, it has been shown that a similar vaccination is also possible for E. multilocularis. Thus, a 14-3-3 and another Em95-vaccine have successfully been tested in the experimental murine model. As the parasite development mainly focuses on a wildlife cycle (wild rodents), a practical application of the vaccine can hardly be implemented. Nevertheless, AE is a very severe disease in humans, therefore one should discuss about the feasibility and the health-economic impact of large-scale vaccination of humans living in areas of high endemicity and thus being at high infection risk.

PMID: 16277036 [PubMed - in process]
 Prev   [ÀÚ·á] Transmission of Toxoplasma: clues from the study of sea otters as sentinels of Toxoplasma gondii flow into the marine environment.
¿î¿µÀÚ
  2005/11/28 
 Next   [ÀÚ·á] Emergence/re-emergence of Echinococcus spp.--a global update.
¿î¿µÀÚ
  2005/11/21 


Copyright 1999-2024 Zeroboard / skin by daerew
151-742 ¼­¿ïƯº°½Ã °ü¾Ç±¸ ½Å¸²9µ¿ »ê56-1 ¼­¿ï´ëÇб³ ¼öÀÇ°ú´ëÇÐ 85µ¿ 802È£
Tel 02-888-2744, Fax 02-888-2754, E-mail cgrb@cgrb.org

Copyright © 2002-2004 CGRB All Rights Reserved